Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
Enanta dosed the first patient in RESOLVE, its global Phase 2b/3 trial of zelicapavir for RSV in high-risk adults. The trial enrolls outpatients with COPD, congestive heart failure, or age 75+, with a minimum of 200 patients in the Phase 2b portion and roughly 660 expected in Phase 3. Prior Phase 2 data showed a 6.7-day symptom-resolution benefit and 0% vs 5% hospitalization rate versus placebo in the HR3 population.
Key figures
- Drug Name
- zelicapavir
- Phase Of Trial
- Phase 2b/3
- Dose
- 800mg once daily for 7 days
- Topline data timing
- Phase 2b topline expected in 2027
- Hr3 symptom benefit days
- 6.7
- Phase2b minimum patients
- 200
- Phase3 expected patients
- 660
- Placebo hospitalization rate
- 5%
- Zelicapavir hospitalization rate
- 0%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.